Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Chunjiang Wang, Yulu Zhou, Ya Zhou & Chao Ye. (2024) Ertapenem-Induced Neurotoxicity: A Literature Review of Clinical Characteristics and Treatment Outcomes. Infection and Drug Resistance 16, pages 3649-3658.
Read now
Read now
Articles from other publishers (15)
Shahid Farooq & Allan Acosta. (2024) Ertapenem-induced encephalopathy in a patient with liver abscess and acute kidney injury. BMJ Case Reports 17:1, pages e256876.
Crossref
Crossref
Alper Alp & Yalkin Dalda. (2021) Ertapenem neurotoxicity in patients with kidney damage: A case report. Acta Facultatis Medicae Naissensis 38:3, pages 299-304.
Crossref
Crossref
Rebecca Adams, Priya Chopra, Richard Miranda & Aaron Calderon. (2020) Ertapenem-induced encephalopathy. BMJ Case Reports 13:6, pages e231875.
Crossref
Crossref
Samuel Deshayes, Antoine Coquerel & Renaud Verdon. (2017) Neurological Adverse Effects Attributable to β-Lactam Antibiotics: A Literature Review. Drug Safety 40:12, pages 1171-1198.
Crossref
Crossref
Yi-Chien Lee, Yun-Jhong Huang, Miao-Chiu Hung, Sheng-Che Hung, Chih-Yen Hsiao, Hui-Ling Cho, Li-Fen Lai, Show-Hwa Tong & Jann-Tay Wang. (2017) Risk factors associated with the development of seizures among adult patients treated with ertapenem: A matched case-control study. PLOS ONE 12:7, pages e0182046.
Crossref
Crossref
Susan J. Lewis, Michael B. Kays & Bruce A. Mueller. (2016) Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy. The Journal of Clinical Pharmacology 56:10, pages 1277-1287.
Crossref
Crossref
Huimin Lin & Samuel T. H. Chew. (2015) Status Epilepticus and Delirium Associated with Ertapenem in a Very Elderly Patient with Chronic Kidney Disease and Silent Ischaemic Cerebrovascular Disease. Drug Safety - Case Reports 2:1.
Crossref
Crossref
Krystle Apodaca, James Baker, Husayn Bin-Bilal, Yosef Raskin & Davin K. Quinn. (2015) Ertapenem-Induced Delirium: A Case Report and Literature Review. Psychosomatics 56:5, pages 561-566.
Crossref
Crossref
K.-H. Lee, Y.-F. Ueng, C.-W. Wu, Y.-C. Chou, Y.-Y. Ng & W.-C. Yang. (2015) The recommended dose of ertapenem poses a potential risk for central nervous system toxicity in haemodialysis patients - case reports and literature reviews. Journal of Clinical Pharmacy and Therapeutics 40:2, pages 240-244.
Crossref
Crossref
Han Yee Neo, Keng Teng Tan & Yew Yoong Ding. (2013) Higher than expected rates of seizures associated with the use of ertapenem in older hospitalized patients. Journal of Clinical Gerontology and Geriatrics 4:1, pages 17-21.
Crossref
Crossref
Dora E. Wiskirchen, Seth T. Housman, Richard Quintiliani, David P. Nicolau & Joseph L. Kuti. (2013) Comparative Pharmacokinetics, Pharmacodynamics, and Tolerability of Ertapenem 1 Gram/Day Administered as a Rapid 5‐Minute Infusion versus the Standard 30‐Minute Infusion in Healthy Adult Volunteers. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33:3, pages 266-274.
Crossref
Crossref
April D. Miller, Amanda M. Ball, P. Brandon Bookstaver, Emily K. Dornblaser & Charles L. Bennett. (2012) Epileptogenic Potential of Carbapenem Agents: Mechanism of Action, Seizure Rates, and Clinical Considerations. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 31:4, pages 408-423.
Crossref
Crossref
Tore Midtvedt. 2011. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
491
508
.
Tore Midtvedt. 2010. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions
445
460
.
. (2009) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 18:5.
Crossref
Crossref